Loading...
Therapeutic Benefits of Tocilizumab Vary in Different Organs of a Patient with AA Amyloidosis
Systemic reactive AA amyloidosis is a life-threatening complication of chronic inflammatory diseases. Anti-interleukin-6 receptor, tocilizumab (TCZ), has been shown to improve clinical symptoms of patients with AA amyloidosis, accompanied with regression of the amyloid deposition. We report a case o...
Na minha lista:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Hindawi Publishing Corporation
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4145365/ https://ncbi.nlm.nih.gov/pubmed/25197587 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2014/823093 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|